AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action
Executive Summary
While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.
You may also be interested in...
Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
GSK Makes I-O Move With Merck KGaA Deal Worth Up To €3.7bn
Already working with Pfizer on the immunotherapy Bavencio, Merck KGaA has bagged another big pharma player in GSK to progress what has been heralded by analysts as the German group's oncology game changer, M7824, which combines two powerful and synergistic anticancer mechanisms into one molecule.
AZ Management Shake-Up Sees CMO Bohen Exit
Sean Bohen is to join Bahija Jallal, Mark Mallon and Ludovic Helfgott in leaving AstraZeneca as the company transitions to a new organizational structure announced last week by CEO Pascal Soriot.